BioMarin Pharmaceutical Inc. (BMRN), a global biotechnology company received the European Medicines Agency (EMA) approval for accelerated assessment of valoctocogene roxaparvovec.
Biotechnology company BioMarin Pharmaceutical (BMRN) posted 1Q results that beat analysts’ estimates. Revenue decreased 3.
Shares in BioMarin Pharmaceutical plunged 36% after the US Food and Drug Administration (FDA) in a surprise move rejected the biotech company’s license …
Global biotech BioMarin Pharmaceutical Inc. (BMRN) has announced updated results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy …
After a stock takes a tumble, wait just a minute before you count it out. While falling share prices could be a sign …
2020 just kicked off, but investors aren’t wasting any time. Rolling up their sleeves and getting straight down to business, they know the …
The world’s population is getting older, rapidly. According to the United Nations, the fastest-growing age group across the world is adults aged 65 …
In a previous article, I talked about the so-called patent cliff and the correlation to the pace of mergers and acquisitions in the pharma …
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced an offering, subject to market and other conditions, of 7,500,000 shares of its common stock in an underwritten …
Oppenheimer analyst Christopher Marai came out today with a few insights on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), after attending the FDA advisory meeting for Kyndrisa, the company’s treatment for Duchenne …